Stomach-wrapping procedure after Barrett's esophagus treatment with endoscopic ablation
Looks at outcomes of the TIF procedure in people with Barrett's esophagus after ablation.
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Registry title
- Outcomes After Transoral Incisionless Fundoplication (TIF) Following Successful Endoscopic Ablation for Barrett's Esophagus
- Status
- Enrolling by invitation
- People taking part
- 50 people, planned
- Started
- 7 Jun 2018
- Expected to end
- 7 Jun 2027
- Type of study
- Observational
- Treatments tested
- TIF
- Record updated
- 15 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Barrett's esophagus that was fully removed by endoscopic ablation. They take PPI acid medicine and want a procedure called TIF instead of lifelong medicine.
- Age
- 18 to 75 years
- Sex
- All sexes
- Disease stage
- Barrett's esophagus confirmed by tissue test, with or without dysplasia (abnormal cells), Prague class >1. Hiatal hernia must be ≤ 2 cm (0.8 in) or Hill grade < 2, unless the hernia is repaired together with TIF.
- Earlier treatment
- Must have had radiofrequency or cryotherapy ablation. Complete removal must be shown on two endoscopies at least 3 months apart, the latest within 6 months. Must currently take PPI therapy.
- Biomarker or test result
- Abnormal acid exposure in the esophagus: acid exposure time > 6% on Bravo pH monitoring (48 - 96 hours).
Main reasons for not taking part
- Age under 18 or over 75 years
- Not able to give informed consent
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age 18 - 75 years
- Known prior diagnosis of histologically-confirmed BE with or without dysplasia (as defined by the presence of specialized columnar epithelium anywhere in the tubular esophagus with >= 1 cm of circumferential involvement or non-circumferential involvement of specialized columnar epithelium) [Prague class >1] and history of initial complete eradication-IM following endoscopic ablation for Barrett's esophagus
- Documentation of complete ablation of BE by endoscopy and histology after radiofrequency or cryotherapy ablation on two endoscopic examinations at least 3 months apart, within most recent endoscopy performed within 6 months. Pathologic diagnosis determined by the expert pathologist at each site
- On PPI therapy, who opt for an intervention over lifelong drug dependence
- Hiatal hernia ≤ 2 cm or Hill grade < 2 [unless patients undergoing combined TIF and hiatal hernia repair]
- Abnormal esophageal acid exposure [Percent esophageal acid exposure time > 6% defined by Bravo ph monitoring (48 - 96 hours study)
- Able to provide informed consent
Who cannot take part
- Age < 18 or > 75 years
- Inability to provide informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- Saowanee NgamruengphongBaltimore, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
Barrett's esophagus (BE) is a precancerous lesion characterized by the replacement of the normal stratified squamous epithelium of the distal esophagus by intestinal metaplasia (IM). Non-dysplastic BE may progress to low-grade dysplasia (LGD), to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). Endoscopic ablation is safe and effective for complete eradication of BE. However, recurrence is common. Cumulative incidence rate of BE recurrence is up to 30% in the third year. Thus, achieving complete eradication of IM, patients should undergo surveillance indefinitely with serial endoscopy to assess for recurrence of BE. In addition, BE patients have been committed to life-long proton pump inhibitor (PPI) therapy, but increasing concerns about adverse effects has led to alternative therapies. Studies have showed that laparoscopic Nissen fundoplication may decrease recurrence of BE after endoscopic ablation. Transoral Incisionless Fundoplication (TIF) is an endoscopic procedure that mechanically creates fundoplication similar to traditional operative Nissen fundoplication. The role of TIF in patients with BE whom underwent successful endoscopic ablation has not been fully investigated.
The group in the trial
- post-ablation Barrett's patients
The patients with known prior diagnosis of histologically-confirmed Barrett's esophagus with or without dysplasia who have documentation of complete remission of Barrett's esophagus by endoscopy and histology after endoscopic ablation
Treatment: TIF
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Outcomes After Transoral Incisionless Fundoplication (TIF) Following Successful Endoscopic Ablation for Barrett's Esophagus: A Pilot Study
- Plain-language title
- Stomach-wrapping procedure after Barrett's esophagus treatment with endoscopic ablationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT04457193, who can take part
- Record updated
- 15 June 2026